Search Press releases Keywords From To 3 Apr 2026 Acquisition of own shares Read More 31 Mar 2026 European Commission approves KYGEVVI[®]▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d) Read More 27 Mar 2026 Acquisition of own shares Read More 27 Mar 2026 UCB presents new BIMZELX[®] (bimekizumab-bkzx) data at AAD demonstrating high rates of durable and complete skin clearance in moderate-to-severe plaque psoriasis Read More 27 Mar 2026 UCB announces new BIMZELX[®] (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa Read More 27 Mar 2026 UCB Annual General Meeting of Shareholders 2026 Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 1 of 62 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
